Tharimmune Inc. develops clinical-stage biotechnology assets while simultaneously executing a new digital-asset treasury strategy. The company plans to purchase Canton Coin, the utility token of the Canton Network, and run a Super Validator node on that blockchain to earn additional tokens. To lead this initiative, Tharimmune appointed Mark Wendland as chief executive officer and Mark Toomey as president, while its existing team continues to advance the firm’s biotech pipeline. Canton Network, which connects major financial institutions such as Goldman Sachs, DTCC, and BNP Paribas, recorded more than 500,000 daily transactions as of 30 September 2025, underscoring the scale of the ecosystem Tharimmune is entering. The $540 million capital raise gives the company significant resources for both token acquisition and general working capital. Shares in the financing were priced at $3.075 each. The securities were sold to accredited institutional investors under Section 4(a)(2) of the Securities Act and were not registered with the SEC.

Total raised

$540M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025